Argenx

This study tests an investigational drug called efgartigimod in 81 adults with systemic sclerosis (scleroderma), a disease that causes skin thickening and organ damage. Participants receive either the drug or a placebo for up to 48 weeks. The main goal is to see if the drug reduc…

This study tests an investigational drug called efgartigimod in children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see how the drug moves through the body, how safe it is, and whether it helps control symptoms. About …

This study tests an IV medicine called efgartigimod in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. About 69 participants will receive either the drug or a placebo for up to 24 weeks, then all wi…

This study tests a new medicine, ARGX-119, in children aged 5 to 17 with spinal muscular atrophy (SMA). The goal is to find the right dose and see if it is safe and helps improve muscle strength and movement. Participants will receive either the study drug or a placebo for 24 wee…

This study tests an IV drug called efgartigimod in teens aged 12 to 18 who have had immune thrombocytopenia (ITP) for over a year. ITP causes low platelet counts, leading to bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet levels. Par…

This program provides efgartigimod PH20 SC to adults with CIDP who cannot join a clinical trial and have not been helped by standard treatments like steroids or immunoglobulins. The goal is to control the disease by reducing nerve inflammation. Treatment continues until the patie…

This study is testing how safe and effective different drug combinations are for people with myasthenia gravis, a condition that causes muscle weakness. Researchers want to find treatments that reduce side effects and improve quality of life. About 70 adults with generalized MG a…

This study tests whether adding empasiprubart to the standard treatment efgartigimod can further improve symptoms in people with generalized myasthenia gravis (gMG) who still have muscle weakness. About 70 adults with a specific antibody type (AChR-Ab positive) will receive the c…

This study is testing a drug called efgartigimod in adults who were recently diagnosed with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. The goal is to see if the drug can quickly reduce symptoms and improve daily activities. Participants will rec…

This study tests a new drug called efgartigimod for people who have kidney transplant rejection caused by antibodies. About 30 adults who had a kidney transplant at least 6 months ago and have active rejection will receive the drug or a placebo as a shot under the skin. They will…

This study tests a new medicine called empasiprubart against the standard treatment (IVIg) for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and numbness. About 218 adults who have previously responded to IVIg will re…

This study is testing an investigational drug called efgartigimod in children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to find the right dose and see how safe it is. Participants will receive injections and be monitored…

This early-stage study tests a new medicine called ARGX-119 in 16 adults with a rare genetic condition (DOK7-CMS) that causes muscle weakness. The main goal is to check if the drug is safe and how the body handles it. Participants will receive either the drug or a placebo, and la…

This study follows 200 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are starting treatment with efgartigimod. Researchers will track changes in disability, grip strength, and quality of life over two years to see how well the drug works in real…

This study tests a new drug called empasiprubart for adults with CIDP, a condition that causes nerve damage and weakness. About 160 people will receive either the drug or a placebo for 6 months, then everyone gets the drug for 2 more years. The goal is to see if it improves disab…

This study follows 100 adults in Italy with generalized myasthenia gravis (gMG) who are already starting treatment with efgartigimod as part of their routine care. Researchers will track changes in symptoms and daily functioning over up to 23 months using patient surveys and doct…

This study is for people aged 2 and older with certain rare genetic forms of congenital myasthenic syndrome (CMS). It does not test a new treatment. Instead, researchers will collect information from up to 4 visits to learn how the disease changes over time and affects daily life…

This study follows about 279 pregnant or breastfeeding women who have taken efgartigimod for myasthenia gravis or CIDP. Researchers will monitor mothers, fetuses, and infants for any health issues, including birth defects. The goal is to better understand the drug's safety during…

This study follows about 680 adults with generalized myasthenia gravis to see how safe efgartigimod is over time. Some participants will take the drug, while others will not. Researchers will compare serious infections and other side effects between the two groups.

This early-stage study is testing the safety of a new drug called ARGX-124 in healthy adults. Researchers will also measure how the drug moves through the body and how the immune system reacts. The study involves 104 participants and lasts up to 23 weeks. It does not aim to treat…